A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
An Open-label Study of the Effect of Continuous Xeloda Therapy in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer
Sponsor: Hoffmann-La Roche
This PHASE2 trial investigates Colorectal Cancer and is currently completed. Hoffmann-La Roche leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .